YCU PR Office, Author at Yokohama City University

2023-02-17

Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice

Background SARS-CoV-2 Omicron variants are highly resistant to vaccine-induced immunity and human monoclonal antibodies. Methods We previously reported that two nanobodies, P17 and P86, potently neutralize SARS-CoV-2 VOCs. In this study, we modified these nanobodies into trimers, called TP17 and TP86 and tested their neutralization activities against Omicron BA.1 and subvariant BA.2 using pseudovirus assays. Next, we used TP17 and TP86 nanobody cocktail to treat ACE2 transgenic mice infected with lethal dose of SARS-CoV-2 strains, original, Delta and Omicron BA.1.

2023-02-15

Imaging characteristics of myocarditis after mRNA-based COVID-19 vaccination: a meta-analysis

Myocarditis following COVID-19 mRNA vaccination is a rare adverse reaction with an incidence rate of approximately 0.0011%.1 Cardiac magnetic resonance imaging (CMR) allows for non-invasive assessment of myocardial tissue characterization, including myocardial oedema and fibrosis, and has high diagnostic accuracy for diagnosing acute myocarditis.2

2023-02-09

Utility of Commercial High Resolution Satellite Imagery for Monitoring General Flowering in Sarawak, Borneo

General flowering (GF), irregular synchronous mass flowering of multiple tree species across multiple families, is a unique biological phenomenon of the mixed lowland dipterocarp forest in Southeast Asia. Characterizing the spatial extent and temporal dynamics of GF is essential for an improved understanding of climate–vegetation interactions and the potential climate change impact on this species-rich rainforest.

2023-02-07

Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis

Aims Both sodium-glucose cotransporter-2 (SGLT-2) inhibitors and mineralocorticoid receptor antagonists (MRAs) have been shown to reduce cardiovascular (CV) event in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). However, little evidence pertains to the benefits of their combined use.